Pages
Products
CAG-Cre AAV (Serotype 1)

CAG-Cre AAV (Serotype 1)

Cat.No. :  AAV00072Z

Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml

Serotype:  AAV Serotype 1 Storage:  -80 ℃

Inquire for Price

AAV Particle Information

Quality Control

Cat. No. AAV00072Z
Description CAG-Cre AAV (Serotype 1) is the serotype 2/1 (with Capsid from AAV1 and ITR from AAV2) which express Cre recombinase under CAG (also known as CBA) promoter which is a combination of the cytomegalovirus (CMV) early enhancer element and chicken beta-actin promoter for high levels of gene expression in mammalian expression vectors. Used as a control.
Serotype AAV Serotype 1
Target Gene CAG-Cre
Application

1. Determination of optimal MOI (multiplicity of infection), administration methods etc.

2. Detection of the infection efficiency of the AAV serotype against a specific cell type or tissue.

3. Using reporter genes to visualize the distribution and expression of AAV vectors in live animals, helping assess the biodistribution and persistence of gene delivery.

Titer Varies lot by lot, typically ≥1x10^12 GC/mL
Size Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.
Quick Inquiry

Background

Publications

Q & A

Customer Reviews

CAG-Cre AAV (serotype 1) is an advanced tool in the field of genetic engineering and therapeutic research. This engineered viral vector, AAV serotype 2/1, ingeniously combines the capsid of AAV1 with the inverted terminal repeats (ITRs) of AAV2. This combination is specifically designed to take advantage of the high transduction efficiency associated with AAV1, especially in muscle cells, and the reliable and efficient replication and packaging properties provided by the ITRs of AAV2. Central to the function of CAG-Cre AAV is the binding of Cre recombinase, a key protein in the Cre-lox recombination system. This enzyme promotes precise site-specific recombination events, allowing for targeted modification of genomic sequences. When delivered to cells, Cre recombinase can excise specific DNA segments flanking the loxP sites, allowing for controlled activation, inactivation, or exchange of genes. The basis for the expression of Cre recombinase in CAG-Cre AAV is the CAG promoter, which consists of a fusion of the cytomegalovirus (CMV) early enhancer element and the chicken β-actin promoter. CAG-Cre AAV (serotype 1) is not only a key research tool for manipulating gene expression in vitro , but also serves as a control in therapeutic and experimental settings.
Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Reliable Performance

This CAG-Cre AAV (Serotype 1) has become a staple in our laboratory for any project requiring precise genetic manipulation.

Canada

05/08/2023

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction